A review on the antagonist Ebola: A prophylactic approach
Ebola virus (EBOV), a member of Filoviridae virus family under the genus Ebolavirus, has emerged as a dangerous and potential threat to human health globally. It causes a severe and deadly hemorrhagic fever in humans and other mammals, called Ebola Virus Disease (EVD). In recent outbreaks of EVD, th...
Gespeichert in:
| Veröffentlicht in: | Biomedicine & pharmacotherapy 2017-12, Vol.96, p.1513-1526 |
|---|---|
| Hauptverfasser: | , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1526 |
|---|---|
| container_issue | |
| container_start_page | 1513 |
| container_title | Biomedicine & pharmacotherapy |
| container_volume | 96 |
| creator | Khan, Fatima Nazish Qazi, Sahar Tanveer, Khushnuma Raza, Khalid |
| description | Ebola virus (EBOV), a member of Filoviridae virus family under the genus Ebolavirus, has emerged as a dangerous and potential threat to human health globally. It causes a severe and deadly hemorrhagic fever in humans and other mammals, called Ebola Virus Disease (EVD). In recent outbreaks of EVD, there has been loss of large numbers of individual’s life. Therefore, EBOV has attracted researchers and increased interests in developing new models for virus evolution, and therapies. The EBOV interacts with the immune system of the host which led to understand how the virus functions and effects immune system behaviour. This article presents an exhaustive review on Ebola research which includes EVD illness, symptoms, transmission patterns, patho-physiology conditions, development of antiviral agents and vaccines, resilient health system, dynamics and mathematical model of EBOV, challenges and prospects for future studies. |
| doi_str_mv | 10.1016/j.biopha.2017.11.103 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7126370</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0753332217337502</els_id><sourcerecordid>1973454803</sourcerecordid><originalsourceid>FETCH-LOGICAL-c463t-8df3df2d6d41db9bc6e381264c14227ff8fc7f6bfed86b8c449beeff2c8485b53</originalsourceid><addsrcrecordid>eNp9kMtqGzEUhkVJqJ20b1DKLLMZR7fRaLoomJCkBUM27VrochTLjEcTaeySt6-ME6fdZHU4t_8_50PoC8ELgom43ixMiONaLygm7YKQUmUf0Jx0Da4Fxu0ZmuO2YTVjlM7QRc4bjHEjmPyIZrSjWDIq5qhbVgn2Af5UcaimNVR6mPRjHEKeqlsTe_2tWlZjKkbPvbZTsJUeS6rt-hM697rP8PklXqLfd7e_bn7Uq4f7nzfLVW25YFMtnWfOUyccJ850xgpgklDBLeGUtt5Lb1svjAcnhZGW884AeE-t5LIxDbtE34-6485swVkYpqR7Naaw1elZRR3U_50hrNVj3Ku2uLAWF4GrF4EUn3aQJ7UN2ULf6wHiLivStYw3XGJWRvlx1KaYcwJ_siFYHairjTpSVwfqipBSPax9_ffE09Ir5rcfoIAqtJPKNsBgwYUEdlIuhvcd_gL9y5Zg</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1973454803</pqid></control><display><type>article</type><title>A review on the antagonist Ebola: A prophylactic approach</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals Complete</source><creator>Khan, Fatima Nazish ; Qazi, Sahar ; Tanveer, Khushnuma ; Raza, Khalid</creator><creatorcontrib>Khan, Fatima Nazish ; Qazi, Sahar ; Tanveer, Khushnuma ; Raza, Khalid</creatorcontrib><description>Ebola virus (EBOV), a member of Filoviridae virus family under the genus Ebolavirus, has emerged as a dangerous and potential threat to human health globally. It causes a severe and deadly hemorrhagic fever in humans and other mammals, called Ebola Virus Disease (EVD). In recent outbreaks of EVD, there has been loss of large numbers of individual’s life. Therefore, EBOV has attracted researchers and increased interests in developing new models for virus evolution, and therapies. The EBOV interacts with the immune system of the host which led to understand how the virus functions and effects immune system behaviour. This article presents an exhaustive review on Ebola research which includes EVD illness, symptoms, transmission patterns, patho-physiology conditions, development of antiviral agents and vaccines, resilient health system, dynamics and mathematical model of EBOV, challenges and prospects for future studies.</description><identifier>ISSN: 0753-3322</identifier><identifier>EISSN: 1950-6007</identifier><identifier>DOI: 10.1016/j.biopha.2017.11.103</identifier><identifier>PMID: 29208326</identifier><language>eng</language><publisher>France: Elsevier Masson SAS</publisher><subject>Animals ; Antiviral Agents - pharmacology ; Antiviral Agents - therapeutic use ; Disease Outbreaks ; Ebola hemorrhagic fever ; Ebola virus ; Ebola virus disease ; Ebolavirus - drug effects ; Hemorrhagic Fever, Ebola - drug therapy ; Hemorrhagic Fever, Ebola - immunology ; Hemorrhagic Fever, Ebola - prevention & control ; Humans ; Resilient healthcare system ; Vaccines - immunology</subject><ispartof>Biomedicine & pharmacotherapy, 2017-12, Vol.96, p.1513-1526</ispartof><rights>2017 Elsevier Masson SAS</rights><rights>Copyright © 2017 Elsevier Masson SAS. All rights reserved.</rights><rights>2017 Elsevier Masson SAS. All rights reserved. 2017 Elsevier Masson SAS</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c463t-8df3df2d6d41db9bc6e381264c14227ff8fc7f6bfed86b8c449beeff2c8485b53</citedby><cites>FETCH-LOGICAL-c463t-8df3df2d6d41db9bc6e381264c14227ff8fc7f6bfed86b8c449beeff2c8485b53</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S0753332217337502$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>230,314,776,780,881,3537,27901,27902,65306</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/29208326$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Khan, Fatima Nazish</creatorcontrib><creatorcontrib>Qazi, Sahar</creatorcontrib><creatorcontrib>Tanveer, Khushnuma</creatorcontrib><creatorcontrib>Raza, Khalid</creatorcontrib><title>A review on the antagonist Ebola: A prophylactic approach</title><title>Biomedicine & pharmacotherapy</title><addtitle>Biomed Pharmacother</addtitle><description>Ebola virus (EBOV), a member of Filoviridae virus family under the genus Ebolavirus, has emerged as a dangerous and potential threat to human health globally. It causes a severe and deadly hemorrhagic fever in humans and other mammals, called Ebola Virus Disease (EVD). In recent outbreaks of EVD, there has been loss of large numbers of individual’s life. Therefore, EBOV has attracted researchers and increased interests in developing new models for virus evolution, and therapies. The EBOV interacts with the immune system of the host which led to understand how the virus functions and effects immune system behaviour. This article presents an exhaustive review on Ebola research which includes EVD illness, symptoms, transmission patterns, patho-physiology conditions, development of antiviral agents and vaccines, resilient health system, dynamics and mathematical model of EBOV, challenges and prospects for future studies.</description><subject>Animals</subject><subject>Antiviral Agents - pharmacology</subject><subject>Antiviral Agents - therapeutic use</subject><subject>Disease Outbreaks</subject><subject>Ebola hemorrhagic fever</subject><subject>Ebola virus</subject><subject>Ebola virus disease</subject><subject>Ebolavirus - drug effects</subject><subject>Hemorrhagic Fever, Ebola - drug therapy</subject><subject>Hemorrhagic Fever, Ebola - immunology</subject><subject>Hemorrhagic Fever, Ebola - prevention & control</subject><subject>Humans</subject><subject>Resilient healthcare system</subject><subject>Vaccines - immunology</subject><issn>0753-3322</issn><issn>1950-6007</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2017</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kMtqGzEUhkVJqJ20b1DKLLMZR7fRaLoomJCkBUM27VrochTLjEcTaeySt6-ME6fdZHU4t_8_50PoC8ELgom43ixMiONaLygm7YKQUmUf0Jx0Da4Fxu0ZmuO2YTVjlM7QRc4bjHEjmPyIZrSjWDIq5qhbVgn2Af5UcaimNVR6mPRjHEKeqlsTe_2tWlZjKkbPvbZTsJUeS6rt-hM697rP8PklXqLfd7e_bn7Uq4f7nzfLVW25YFMtnWfOUyccJ850xgpgklDBLeGUtt5Lb1svjAcnhZGW884AeE-t5LIxDbtE34-6485swVkYpqR7Naaw1elZRR3U_50hrNVj3Ku2uLAWF4GrF4EUn3aQJ7UN2ULf6wHiLivStYw3XGJWRvlx1KaYcwJ_siFYHairjTpSVwfqipBSPax9_ffE09Ir5rcfoIAqtJPKNsBgwYUEdlIuhvcd_gL9y5Zg</recordid><startdate>201712</startdate><enddate>201712</enddate><creator>Khan, Fatima Nazish</creator><creator>Qazi, Sahar</creator><creator>Tanveer, Khushnuma</creator><creator>Raza, Khalid</creator><general>Elsevier Masson SAS</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>201712</creationdate><title>A review on the antagonist Ebola: A prophylactic approach</title><author>Khan, Fatima Nazish ; Qazi, Sahar ; Tanveer, Khushnuma ; Raza, Khalid</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c463t-8df3df2d6d41db9bc6e381264c14227ff8fc7f6bfed86b8c449beeff2c8485b53</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2017</creationdate><topic>Animals</topic><topic>Antiviral Agents - pharmacology</topic><topic>Antiviral Agents - therapeutic use</topic><topic>Disease Outbreaks</topic><topic>Ebola hemorrhagic fever</topic><topic>Ebola virus</topic><topic>Ebola virus disease</topic><topic>Ebolavirus - drug effects</topic><topic>Hemorrhagic Fever, Ebola - drug therapy</topic><topic>Hemorrhagic Fever, Ebola - immunology</topic><topic>Hemorrhagic Fever, Ebola - prevention & control</topic><topic>Humans</topic><topic>Resilient healthcare system</topic><topic>Vaccines - immunology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Khan, Fatima Nazish</creatorcontrib><creatorcontrib>Qazi, Sahar</creatorcontrib><creatorcontrib>Tanveer, Khushnuma</creatorcontrib><creatorcontrib>Raza, Khalid</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Biomedicine & pharmacotherapy</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Khan, Fatima Nazish</au><au>Qazi, Sahar</au><au>Tanveer, Khushnuma</au><au>Raza, Khalid</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>A review on the antagonist Ebola: A prophylactic approach</atitle><jtitle>Biomedicine & pharmacotherapy</jtitle><addtitle>Biomed Pharmacother</addtitle><date>2017-12</date><risdate>2017</risdate><volume>96</volume><spage>1513</spage><epage>1526</epage><pages>1513-1526</pages><issn>0753-3322</issn><eissn>1950-6007</eissn><abstract>Ebola virus (EBOV), a member of Filoviridae virus family under the genus Ebolavirus, has emerged as a dangerous and potential threat to human health globally. It causes a severe and deadly hemorrhagic fever in humans and other mammals, called Ebola Virus Disease (EVD). In recent outbreaks of EVD, there has been loss of large numbers of individual’s life. Therefore, EBOV has attracted researchers and increased interests in developing new models for virus evolution, and therapies. The EBOV interacts with the immune system of the host which led to understand how the virus functions and effects immune system behaviour. This article presents an exhaustive review on Ebola research which includes EVD illness, symptoms, transmission patterns, patho-physiology conditions, development of antiviral agents and vaccines, resilient health system, dynamics and mathematical model of EBOV, challenges and prospects for future studies.</abstract><cop>France</cop><pub>Elsevier Masson SAS</pub><pmid>29208326</pmid><doi>10.1016/j.biopha.2017.11.103</doi><tpages>14</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0753-3322 |
| ispartof | Biomedicine & pharmacotherapy, 2017-12, Vol.96, p.1513-1526 |
| issn | 0753-3322 1950-6007 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7126370 |
| source | MEDLINE; Elsevier ScienceDirect Journals Complete |
| subjects | Animals Antiviral Agents - pharmacology Antiviral Agents - therapeutic use Disease Outbreaks Ebola hemorrhagic fever Ebola virus Ebola virus disease Ebolavirus - drug effects Hemorrhagic Fever, Ebola - drug therapy Hemorrhagic Fever, Ebola - immunology Hemorrhagic Fever, Ebola - prevention & control Humans Resilient healthcare system Vaccines - immunology |
| title | A review on the antagonist Ebola: A prophylactic approach |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-10T12%3A25%3A49IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=A%20review%20on%20the%20antagonist%20Ebola:%20A%20prophylactic%20approach&rft.jtitle=Biomedicine%20&%20pharmacotherapy&rft.au=Khan,%20Fatima%20Nazish&rft.date=2017-12&rft.volume=96&rft.spage=1513&rft.epage=1526&rft.pages=1513-1526&rft.issn=0753-3322&rft.eissn=1950-6007&rft_id=info:doi/10.1016/j.biopha.2017.11.103&rft_dat=%3Cproquest_pubme%3E1973454803%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1973454803&rft_id=info:pmid/29208326&rft_els_id=S0753332217337502&rfr_iscdi=true |